Samuel Milbury - Profile and Investment Details

Investor Profile

Samuel Milbury is a Corporate Venture Capital based in New York, United States with a diverse investment portfolio that includes companies such as GlobeImmune, Orchestra BioMed, Armada Water Assets, Motus GI, Helocyte, Outstanding Foods, Hydrofarm, Adgero Biopharmaceuticals, Deem, BackBeat Medical, Organovo Holdings, Kintara Therapeutics, Caliber Therapeutics, PROLOR Biotech, DarioHealth, InVivo Therapeutics, Corbus Pharmaceuticals, MATINAS BIOPHARMA, Aerami Therapeutics. Over time, Samuel Milbury has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Samuel Milbury is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Consumer Goods, Android, Food Processing, Wholesale, Biotech, Cloud Computing, Diabetes, Hydroponics, Medical Device, Software, Manufacturing, Healthcare, Biotechnology, Market Research, Productivity Software, AgTech, Nutrition, Food and Beverage, Agriculture, Investment Banking, Farming, Snack Food, Medical, Therapeutics, Packaged Goods may find it worthwhile to explore potential connections with Samuel Milbury, as their portfolio suggests a familiarity and interest in this area.

Understanding Samuel Milbury’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.